Capricor Therapeutics (NASDAQ:CAPR) Trading 5.2% Higher - Here's What Happened

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s share price rose 5.2% on Monday . The company traded as high as $18.94 and last traded at $18.69. Approximately 839,585 shares traded hands during trading, a decline of 22% from the average daily volume of 1,080,003 shares. The stock had previously closed at $17.77.

Wall Street Analyst Weigh In

CAPR has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. Maxim Group lifted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Finally, Oppenheimer reissued an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.60.

Capricor Therapeutics Price Performance

The stock has a 50-day simple moving average of $7.76 and a 200-day simple moving average of $6.16. The stock has a market cap of $626.15 million, a PE ratio of -22.51 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million during the quarter, compared to analysts' expectations of $4.51 million. As a group, equities research analysts anticipate that Capricor Therapeutics Inc will post -1.13 EPS for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business's stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.00% of the company's stock.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after buying an additional 200,499 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Capricor Therapeutics during the 2nd quarter worth $426,000. Bank of New York Mellon Corp boosted its stake in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after acquiring an additional 9,040 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics in the second quarter valued at $147,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.